Penicillamine
- Generic Name
- Penicillamine
- Brand Names
- Cuprimine, Depen
- Drug Type
- Small Molecule
- Chemical Formula
- C5H11NO2S
- CAS Number
- 52-67-5
- Unique Ingredient Identifier
- GNN1DV99GX
- Background
Penicillamine is a pharmaceutical of the chelator class. The pharmaceutical form is D-penicillamine, as L-penicillamine is toxic (it inhibits the action of pyridoxine). It is an α-amino acid metabolite of penicillin, although it has no antibiotic properties.
- Indication
For treatment of Wilson's disease, cystinuria and active rheumatoid arthritis.
- Associated Conditions
- Cystinuria, Lead Poisoning, Wilson's Disease, Refractory Rheumatoid arthritis, Severe Rheumatoid arthritis
- Associated Therapies
- -
Safety and Superiority of Penicillamine in Radiosensitization of Recurrent Head and Neck Cancer
- First Posted Date
- 2023-10-27
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Nanfang Hospital, Southern Medical University
- Target Recruit Count
- 10
- Registration Number
- NCT06103617
- Locations
- 🇨🇳
Southern medical university, Guangzhou, Guangdong, China
🇨🇳Nanfang Hospital, Sourthern Medical University, Guangzhou, China
The Individual Therapy for Patients With Wilson's Disease
- Conditions
- Interventions
- First Posted Date
- 2019-05-21
- Last Posted Date
- 2019-05-21
- Target Recruit Count
- 400
- Registration Number
- NCT03957720
- Locations
- 🇨🇳
econd Affiliated Hospital,Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
Penicillamine, Low Copper Diet, and Radiation Therapy in Treating Patients With Glioblastoma
- Conditions
- First Posted Date
- 2004-08-18
- Last Posted Date
- 2012-05-03
- Target Recruit Count
- 40
- Registration Number
- NCT00003751
- Locations
- 🇺🇸
Johns Hopkins Oncology Center, Baltimore, Maryland, United States
🇺🇸Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.